The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Anthony M CirrincioneAlexandra M PoosBachisio ZicchedduMarcella KaddouraMarc-Andrea BaertschKylee H MaclachlanMonika ChojnackaBenjamin T DiamondLukas JohnPhilipp ReichertStefanie HuhnPatrick BlaneyDylan C GaglerKarsten RippeYanming ZhangAhmet DoganAlexander M LesokhinFaith E DaviesHartmut GoldschmidtRoland FenkKatja C WeiselElias Karl MaiNeha KordeGareth J MorganSaad Z UsmaniCarl Ola LandgrenMarc S RaabNiels WeinholdFrancesco MauraPublished in: Blood (2024)
Acquisition of a hyperdiploid (HY) karyotype or immunoglobulin heavy chain (IGH) translocations are considered key initiating events in multiple myeloma (MM). To explore if other genomic events can precede these events, we analyzed whole-genome sequencing (WGS) data from 1173 MM samples. Integrating molecular time and structural variants (SV) within early chromosomal duplications, we indeed identified pre-gain deletions in 9.4% of HY patients without IGH translocations, challenging HY as the earliest somatic event. Remarkably, these deletions affected tumor suppressor genes (TSG) and/or oncogenes in 2.4% of HY patients without IGH translocations, supporting their role in MM pathogenesis. Furthermore, our study points to post-gain deletions as novel driver mechanisms in MM. Using multi-omics approaches to investigate their biological impact, we found associations with poor clinical outcome in newly diagnosed patients and profound effects on both oncogene and TSG activity, despite the diploid gene status. Overall, this study provides novel insights into the temporal dynamics of genomic alterations in MM.